External open innovation partner programIdentification of validated targets, small molecules or phenotypic screening for the treatment of NASH (Non-alcoholic steatohepatitis)
For the treatment of NASH, we are looking for:
- Drug targets: newly identified, druggable (tractable with small chemical compounds), disease-relevant (validated with a series of studies) targets
- Hit / Lead compounds: small chemical compounds which show desirable activity on a) novel drug targets or b) known targets for which no small chemical compounds have been identified
- Phenotypic screening systems - newly established, disease-relevant (in the cell origin, cell functions, stimuli, culture conditions, readouts), high throughput screening-compatible cell culture systems
We are interested in research programs which may lead to the development of drugs that fulfill the following target product profile (TPP):
- a) orally active, first-in-class small chemical entities,
- b) satisfy the unmet medical needs with a clear advantage over the current therapy,
- c)reduce NAFLD activity score or improve NAFLD fibrosis score
We are not interested in:
- Any modalities other than small chemical compounds
- Common mechanisms of fibrotic diseases (not liver-specific)
- Drug targets not accompanied by validation of disease relevance
- Undruggable targets
- Drug targets which have a risk of safety issues when systemically modulated
- Drug targets with known small chemical drugs
- Phenotypic screening systems not accompanied by validation of disease relevance
All proposals will be assessed by our Research &Development team. Based on the level of interest within the Company research portfolio and strategic fit, we will enter into discussion with selected candidate(s), potentially leading to partnership agreements or collaborations.
Proponents that submit proposals of interest will be contacted within 8 weeks of submission to clarify additional details.
Submit a proposal in a form which is available online (it takes about 15 minutes).The proposal should be brief, sufficient to provide the main body of the proposal and its innovativeness. The applicant should also provide information about his or her critical knowledge that is applicable for the project, and how the knowledge could be supplemented (i.e., what is additionally required to complete the project). The applicants are strongly encouraged to give us additional information including references or other materials to facilitate the evaluation process.
The Company will not share the information beyond its own staff; your initial proposal should contain only non-confidential information.
If your proposal is selected, the Company is open to complete a Confidentiality Disclosure Agreement (CDA).
Biowebspin is the #1 academia-industry partnering network in Life Sciences.
For academics, Biowebspin is the platform to find industrial partners and funding for their research projects matching R&D programs of more than 500 leading Life Sciences companies and foundations.